Neuronetics Names Todd Cushman as Vice President, Business Development

NEXT STORY
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
PREV STORY
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018

SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease ...

author_avatar
NASDAQ Market News

Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer

No Significant CA4P Drug Safety Issues IdentifiedInitial Efficacy in Favor of CA4P, with 22% ...

author_avatar
NASDAQ Market News

Agios Reports Third Quarter 2018 Financial Results

– Supplemental New Drug Application Submission for Single Agent TIBSOVO® (ivosidenib) in Newly Diagnosed ...

author_avatar
NASDAQ Market News